Kok Wai Giang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kok Wai Giang has a total of 76 co-authors. Here are the top co-authors by number of shared publications:
- Zacharias Mandalenakis
Department of Molecular and Clinical Medicine, Sahlgrenska Academy University of Gothenburg Gothenburg Sweden
13 shared publications - Mikael Dellborg
Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg , Gothenburg
9 shared publications - Maria Fedchenko
Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Sweden; Department of Medicine, Emergency Medicine and Geriatrics, Sahlgrenska University Hospital/Östra Hospital, Region Västra Götaland, Gothenburg, Sweden
6 shared publications - Peter Eriksson
Sahlgrenska University Hospital
6 shared publications - Annika Rosengren
Department of Molecular and Clinical Medicine, Sahlgrenska Academy, University of Gothenburg and Sahlgrenska University Hospital, Gothenburg, Sweden
5 shared publications Peter Eriksson
Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg , Diagnosvägen 11, SE-416 50 Gothenburg
5 shared publications
Latest Publications
- Open Access
- 21 April 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (8) , e045788
Long‐Term Outcomes of Antithrombotic Treatment in a Cohort of 864 Patients With Fontan Circulation
Background: An effective antithrombotic strategy for patients with univentricular heart is required. We determined the prevalence of antithrombotic treatment and survival in patients with Fontan circulation, with secondary outcomes mortality, cardiovascular disease, acute myocardial infarction, and ischemic stroke. Methods: We retrospectively included patients with univentricular heart born in Sweden between January 1, 1970, and December 31, 2017. Data from the National Patient Register, the Cause of Death Register, and the Prescribed Drug Register were used. Patients who underwent total cavopulmonary connection surgery, resulting in Fontan circulation, were included and divided into groups based on treatment: anticoagulation, antiplatelets, and no antithrombotic therapy. Results: In total, 864 patients (median [interquartile range] 14.4 [3.9–24.9] years follow‐up) were included, 511 of whom (59%) were men. Thirty‐six percent received no antithrombotic treatment, and the mortality rate during the follow‐up was 58%. Among the patients treated with antithrombotic treatment, 75% received antiplatelets, with a 4% mortality rate. The mortality incidence rate was 2.40 (95% CI, 1.49–3.67) for antithrombotic treatment and 49.42 (95% CI, 42.50–57.15) without. The hazard ratio for mortality was 22.32 (95% CI, 14.04–35.48) without antithrombotic treatment. The incidence rate of ischemic stroke was 2.45 (95% CI, 1.52–3.75) with antithrombotic treatment and 2.47 (95% CI, 1.13–4.68) without. The incidence rate of acute myocardial infarction was 0.69 (95% CI, 0.25–1.50) with antithrombotic treatment and 2.76 (95% CI, 1.32–5.07) without treatment. Conclusions: Treatment with antiplatelets was associated with lower mortality compared with no antithrombotic treatment.
- 21 April 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (8) , e045788
Open AccessLong‐Term Outcomes of Antithrombotic Treatment in a Cohort of 864 Patients With Fontan Circulation
Background: An effective antithrombotic strategy for patients with univentricular heart is required. We determined the prevalence of antithrombotic treatment and survival in patients with Fontan circulation, with secondary outcomes mortality, cardiovascular disease, acute myocardial infarction, and ischemic stroke. Methods: We retrospectively included patients with univentricular heart born in Sweden between January 1, 1970, and December 31, 2017. Data from the National Patient Register, the Cause of Death Register, and the Prescribed Drug Register were used. Patients who underwent total cavopulmonary connection surgery, resulting in Fontan circulation, were included and divided into groups based on treatment: anticoagulation, antiplatelets, and no antithrombotic therapy. Results: In total, 864 patients (median [interquartile range] 14.4 [3.9–24.9] years follow‐up) were included, 511 of whom (59%) were men. Thirty‐six percent received no antithrombotic treatment, and the mortality rate during the follow‐up was 58%. Among the patients treated with antithrombotic treatment, 75% received antiplatelets, with a 4% mortality rate. The mortality incidence rate was 2.40 (95% CI, 1.49–3.67) for antithrombotic treatment and 49.42 (95% CI, 42.50–57.15) without. The hazard ratio for mortality was 22.32 (95% CI, 14.04–35.48) without antithrombotic treatment. The incidence rate of ischemic stroke was 2.45 (95% CI, 1.52–3.75) with antithrombotic treatment and 2.47 (95% CI, 1.13–4.68) without. The incidence rate of acute myocardial infarction was 0.69 (95% CI, 0.25–1.50) with antithrombotic treatment and 2.76 (95% CI, 1.32–5.07) without treatment. Conclusions: Treatment with antiplatelets was associated with lower mortality compared with no antithrombotic treatment.
- Open Access
- 2 April 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Valvular and Structural Heart Disease
- Vol. 2 (2)
The contemporary and historical burden of arrhythmias in patients with congenital heart disease
Background: Arrhythmias constitute a significant concern in patients with congenital heart disease (CHD) but temporal trends remain unknown. Aims: To describe the burden of arrhythmias and dissect the impact of era of birth, lesion complexity, and age in both children and adults with CHD born in Sweden. Methods and results: In a population-based cohort study, patients diagnosed with CHD (n = 63 431) born in 1970–2017 were identified in the Swedish National Patient Register. Each patient was matched by age and sex with 10 control subjects (n = 583 100) from the general population. Fine–Gray competing risk and Cox proportional-hazards regression were used; risk estimates were compared with matched controls. During median follow-up of 19 years (total range: 0–53 years), 1895 new events of supraventricular arrhythmias were registered, yielding a hazard ratio (HR) of 8.0 [95% confidence interval (CI) 7.6–8.5], along with 371 new ventricular arrhythmias (HR 13.0; 95% CI 11.2–15.2). Complex CHD was associated with higher risk, irrespective of type, than non-complex CHD, and patients born in 1990 or later displayed lower risk for both supraventricular and ventricular arrhythmias, irrespective of age and CHD complexity, than those born before 1990. Patients aged 18–39 years with non-complex and complex CHD born before 1990 displayed HRs of 6.9 (95% CI 6.1–7.8) and 23.9 (95% CI 19.4–29.5) for supraventricular arrhythmias, respectively, versus 3.2 (95% CI 2.7–3.9) and 13.9 (95% CI 9.8–19.7) in those born in 1990 or later. Conclusions: The risk of arrhythmias was generally high across the CHD population and increased with increasing age and lesion complexity. Importantly, patients born in 1990 or later demonstrated lower risk for both supraventricular and ventricular arrhythmias than those born before 1990.
- 2 April 2026
- Published by Oxford University Press (OUP) in European Heart Journal - Valvular and Structural Heart Disease
- Vol. 2 (2)
Open AccessThe contemporary and historical burden of arrhythmias in patients with congenital heart disease
Background: Arrhythmias constitute a significant concern in patients with congenital heart disease (CHD) but temporal trends remain unknown. Aims: To describe the burden of arrhythmias and dissect the impact of era of birth, lesion complexity, and age in both children and adults with CHD born in Sweden. Methods and results: In a population-based cohort study, patients diagnosed with CHD (n = 63 431) born in 1970–2017 were identified in the Swedish National Patient Register. Each patient was matched by age and sex with 10 control subjects (n = 583 100) from the general population. Fine–Gray competing risk and Cox proportional-hazards regression were used; risk estimates were compared with matched controls. During median follow-up of 19 years (total range: 0–53 years), 1895 new events of supraventricular arrhythmias were registered, yielding a hazard ratio (HR) of 8.0 [95% confidence interval (CI) 7.6–8.5], along with 371 new ventricular arrhythmias (HR 13.0; 95% CI 11.2–15.2). Complex CHD was associated with higher risk, irrespective of type, than non-complex CHD, and patients born in 1990 or later displayed lower risk for both supraventricular and ventricular arrhythmias, irrespective of age and CHD complexity, than those born before 1990. Patients aged 18–39 years with non-complex and complex CHD born before 1990 displayed HRs of 6.9 (95% CI 6.1–7.8) and 23.9 (95% CI 19.4–29.5) for supraventricular arrhythmias, respectively, versus 3.2 (95% CI 2.7–3.9) and 13.9 (95% CI 9.8–19.7) in those born in 1990 or later. Conclusions: The risk of arrhythmias was generally high across the CHD population and increased with increasing age and lesion complexity. Importantly, patients born in 1990 or later demonstrated lower risk for both supraventricular and ventricular arrhythmias than those born before 1990.
- Open Access
- 6 January 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (1) , e043652
Trends in Congenital Heart Disease Hospitalizations: What Nearly 50 Years of Longitudinal Data and Segmented Regression Reveal
Background: Understanding long‐term health care utilization patterns in congenital heart disease (CHD) is essential for optimizing care delivery. While previous studies often assume linear trends, such assumptions could provide flawed analysis if abrupt changes in treatment or care occur, causing nonlinearity in trends. This study aims to determine if and where significant nonlinearity exists in hospitalization trends within the CHD pediatric population. Methods: Using national Swedish registers, we conducted a retrospective cohort study using segmented regression analysis of pediatric CHD health care utilization from infancy through adolescence, stratified by disease complexity. Breakpoints were identified to assess changes in trend over time, and subgroup analyses compared segmented and linear regression models. Results: Segmented regression revealed distinct utilization patterns across age groups, with highest health care use in infancy followed by a progressive decline through childhood and adolescence. Contrary to prior research, utilization declined over time regardless of CHD complexity. Identified breakpoints within the general CHD pediatric population in 1978, 1985, 1992, and 2003 aligned with key developments in CHD care. Conclusions: These findings challenge prevailing assumptions of increasing health care use over time among the pediatric CHD population. Given the identified breakpoints, caution is warranted when conducting comparative analyses that span these periods, as doing so may obscure meaningful shifts in underlying trends.
- 6 January 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (1) , e043652
Open AccessTrends in Congenital Heart Disease Hospitalizations: What Nearly 50 Years of Longitudinal Data and Segmented Regression Reveal
Background: Understanding long‐term health care utilization patterns in congenital heart disease (CHD) is essential for optimizing care delivery. While previous studies often assume linear trends, such assumptions could provide flawed analysis if abrupt changes in treatment or care occur, causing nonlinearity in trends. This study aims to determine if and where significant nonlinearity exists in hospitalization trends within the CHD pediatric population. Methods: Using national Swedish registers, we conducted a retrospective cohort study using segmented regression analysis of pediatric CHD health care utilization from infancy through adolescence, stratified by disease complexity. Breakpoints were identified to assess changes in trend over time, and subgroup analyses compared segmented and linear regression models. Results: Segmented regression revealed distinct utilization patterns across age groups, with highest health care use in infancy followed by a progressive decline through childhood and adolescence. Contrary to prior research, utilization declined over time regardless of CHD complexity. Identified breakpoints within the general CHD pediatric population in 1978, 1985, 1992, and 2003 aligned with key developments in CHD care. Conclusions: These findings challenge prevailing assumptions of increasing health care use over time among the pediatric CHD population. Given the identified breakpoints, caution is warranted when conducting comparative analyses that span these periods, as doing so may obscure meaningful shifts in underlying trends.
- Open Access
- 8 February 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
- Vol. 11 (5) , 614-621
Mortality and morbidity after transcatheter aortic valve implantation compared to an age- and sex-matched control population: a population-based study from the SWEDEHEART registry
Introduction: Data are lacking about the risk for death and major adverse cardiovascular events (MACE) after transcatheter aortic valve implantation (TAVI), compared to the general population. Therefore, we assessed the risk for all-cause death and MACE after TAVI in patients aged 65 years and older, in comparison to an age- and sex-matched control population. Methods and results: In total, 5924 TAVI patients and 10 928 matched controls [mean age 82.1, standard deviation (SD) 6.0, and 81.9, SD 6.1, respectively] were included from 2014 to 2020. The SWEDEHEART registry and four mandatory national registers were used to collect data. Cox regression models were used to assess the association with all-cause mortality and MACE risk. In total, 1410 (23.8%) of the TAVI patients and 2115 (19.4%) controls died during the follow-up period. Median follow-up was 1.9 years (inter quartile range 0.9–3.3) respectively. The crude mortality and MACE risks were higher in TAVI patients than in controls {hazard ratios 1.27 [95% Confidence interval (CI): 1.19–1.36] and HR 1.44 (95% CI: 1.35–1.53), respectively}. After adjustment, there was a lower risk for both mortality and MACE in TAVI patients [adjusted hazard ratio (aHR) 0.77 (95% CI: 0.71–0.84) and aHR 0.90 (95% CI: 0.83–0.98), respectively]. Conclusion: After adjustments for comorbidities, the mortality risk was lower in TAVI patients, compared with an age- and sex-matched control population. These findings suggest that the high burden of comorbidities in TAVI patients has a strong impact on the risk for mortality and MACE after TAVI.
- 8 February 2025
- Published by Oxford University Press (OUP) in European Heart Journal - Quality of Care and Clinical Outcomes
- Vol. 11 (5) , 614-621
Open AccessMortality and morbidity after transcatheter aortic valve implantation compared to an age- and sex-matched control population: a population-based study from the SWEDEHEART registry
Introduction: Data are lacking about the risk for death and major adverse cardiovascular events (MACE) after transcatheter aortic valve implantation (TAVI), compared to the general population. Therefore, we assessed the risk for all-cause death and MACE after TAVI in patients aged 65 years and older, in comparison to an age- and sex-matched control population. Methods and results: In total, 5924 TAVI patients and 10 928 matched controls [mean age 82.1, standard deviation (SD) 6.0, and 81.9, SD 6.1, respectively] were included from 2014 to 2020. The SWEDEHEART registry and four mandatory national registers were used to collect data. Cox regression models were used to assess the association with all-cause mortality and MACE risk. In total, 1410 (23.8%) of the TAVI patients and 2115 (19.4%) controls died during the follow-up period. Median follow-up was 1.9 years (inter quartile range 0.9–3.3) respectively. The crude mortality and MACE risks were higher in TAVI patients than in controls {hazard ratios 1.27 [95% Confidence interval (CI): 1.19–1.36] and HR 1.44 (95% CI: 1.35–1.53), respectively}. After adjustment, there was a lower risk for both mortality and MACE in TAVI patients [adjusted hazard ratio (aHR) 0.77 (95% CI: 0.71–0.84) and aHR 0.90 (95% CI: 0.83–0.98), respectively]. Conclusion: After adjustments for comorbidities, the mortality risk was lower in TAVI patients, compared with an age- and sex-matched control population. These findings suggest that the high burden of comorbidities in TAVI patients has a strong impact on the risk for mortality and MACE after TAVI.
- Open Access
- 10 October 2024
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 4 (6) , oeae089
Risk of venous thromboembolism in patients with congenital heart disease: a nationwide, register-based, case–control study
Aims: Patients with congenital heart disease (CHD) have an increased risk of developing acquired cardiovascular diseases. However, the risk of venous thromboembolism (VTE) in patients with CHD is unknown. We aimed to investigate the incidence and risk of VTE in patients with CHD compared with matched controls without CHD. Methods and results: Data from Swedish health registers were used to identify all patients with CHD between 1970 and 2017 in Sweden. Each patient with CHD was matched with 10 controls from the Swedish Total Population Register. The primary outcome of the study was an event of VTE. Follow-up was from birth until VTE, death, or the end of the study (2017). Cox proportional hazard models were used to investigate the risk of VTE in patients with CHD and controls. A total of 67 814 patients with CHD and 583 709 matched controls were identified and included in the study. During a mean follow-up of 15.9 (SD ± 12.5) years, 554 (0.8%) patients with CHD and 1571 (0.3%) controls developed VTE. The risk of VTE was 3.3 [95% confidence interval [CI] 2.6–3.4) times higher in patients with CHD than in controls. Patients with conotruncal defects had the highest risk of VTE (hazard ratio 7.06, 95% CI 5.52–9.03). Conclusion: In our nationwide study, we found that the risk of VTE in patients with CHD was more than three times higher than in matched controls. The highest risk of VTE was in patients with the most complex lesions. Further research is crucial to clarify the underlying risk factors and prevent VTE in patients with CHD.
- 10 October 2024
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 4 (6) , oeae089
Open AccessRisk of venous thromboembolism in patients with congenital heart disease: a nationwide, register-based, case–control study
Aims: Patients with congenital heart disease (CHD) have an increased risk of developing acquired cardiovascular diseases. However, the risk of venous thromboembolism (VTE) in patients with CHD is unknown. We aimed to investigate the incidence and risk of VTE in patients with CHD compared with matched controls without CHD. Methods and results: Data from Swedish health registers were used to identify all patients with CHD between 1970 and 2017 in Sweden. Each patient with CHD was matched with 10 controls from the Swedish Total Population Register. The primary outcome of the study was an event of VTE. Follow-up was from birth until VTE, death, or the end of the study (2017). Cox proportional hazard models were used to investigate the risk of VTE in patients with CHD and controls. A total of 67 814 patients with CHD and 583 709 matched controls were identified and included in the study. During a mean follow-up of 15.9 (SD ± 12.5) years, 554 (0.8%) patients with CHD and 1571 (0.3%) controls developed VTE. The risk of VTE was 3.3 [95% confidence interval [CI] 2.6–3.4) times higher in patients with CHD than in controls. Patients with conotruncal defects had the highest risk of VTE (hazard ratio 7.06, 95% CI 5.52–9.03). Conclusion: In our nationwide study, we found that the risk of VTE in patients with CHD was more than three times higher than in matched controls. The highest risk of VTE was in patients with the most complex lesions. Further research is crucial to clarify the underlying risk factors and prevent VTE in patients with CHD.
- Open Access
- 3 September 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (17) , e032813
Ischemic Stroke in Patients With Congenital Heart Disease and Atrial Fibrillation
Background: Atrial fibrillation (AF) is a common arrhythmia in patients with congenital heart disease (CHD), but little is known about the risk for ischemic stroke among younger patients with CHD (aged <65 years) with AF. Methods and Results: Using data from the National Swedish Patient Register and Cause of Death Register, we identified all patients with both CHD and AF born in Sweden between 1970 and 2017. The Swedish total population register was used to identify age‐ and sex‐matched patients without CHD; those with AF were used as controls. Bottos hierarchical classification was used to define CHD as either complex or noncomplex. Controls were followed from the onset of AF until the index ischemic stroke, death, or end of study (December 31, 2017). We identified 951 patients with CHD with AF and 606 controls with AF. Among patients with both CHD and AF, 2.9% of patients (n=28) developed ischemic stroke, compared with 0.5% (n=3) in controls. When adjusted for age, sex, hypertension, and heart failure, a hazard ratio (HR) of 5.16 (95% CI, 1.52–17.46) was acquired. The HR in noncomplex CHD was 3.84 (95% CI, 1.07–13.84), and the HR in complex CHD was 8.34 (95% CI, 2.27–30.57). For patients born in 1970 to 1989, the HR in ischemic stroke was 7.35 (95% CI, 1.70–31.75). No adjusted HR for patients with CHD born in 1990 to 2017 could be acquired due to few events. Conclusions: The risk for ischemic stroke may be 5 times higher in patients with both CHD and AF compared with patients without CHD with AF. However, larger studies may be needed to confirm/refute these results.
- 3 September 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (17) , e032813
Open AccessIschemic Stroke in Patients With Congenital Heart Disease and Atrial Fibrillation
Background: Atrial fibrillation (AF) is a common arrhythmia in patients with congenital heart disease (CHD), but little is known about the risk for ischemic stroke among younger patients with CHD (aged <65 years) with AF. Methods and Results: Using data from the National Swedish Patient Register and Cause of Death Register, we identified all patients with both CHD and AF born in Sweden between 1970 and 2017. The Swedish total population register was used to identify age‐ and sex‐matched patients without CHD; those with AF were used as controls. Bottos hierarchical classification was used to define CHD as either complex or noncomplex. Controls were followed from the onset of AF until the index ischemic stroke, death, or end of study (December 31, 2017). We identified 951 patients with CHD with AF and 606 controls with AF. Among patients with both CHD and AF, 2.9% of patients (n=28) developed ischemic stroke, compared with 0.5% (n=3) in controls. When adjusted for age, sex, hypertension, and heart failure, a hazard ratio (HR) of 5.16 (95% CI, 1.52–17.46) was acquired. The HR in noncomplex CHD was 3.84 (95% CI, 1.07–13.84), and the HR in complex CHD was 8.34 (95% CI, 2.27–30.57). For patients born in 1970 to 1989, the HR in ischemic stroke was 7.35 (95% CI, 1.70–31.75). No adjusted HR for patients with CHD born in 1990 to 2017 could be acquired due to few events. Conclusions: The risk for ischemic stroke may be 5 times higher in patients with both CHD and AF compared with patients without CHD with AF. However, larger studies may be needed to confirm/refute these results.
- Open Access
- 31 August 2024
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 4 (5) , oeae077
Marital status, educational level, and mid-term mortality risk in 5924 patients after transcatheter aortic valve implantation
Aims: There is scarce knowledge about the association between social factors and mid-term outcome in older patients undergoing transaortic valve implantation (TAVI). Our aim in this study is to explore associations between marital status, educational level, and mortality risk in patients after TAVI. Methods and results: Patients aged ≥65 who underwent TAVI in Sweden during 2014–2020 were identified from the SWEDEHEART registry. Social factors and comorbidities were collected from mandatory national registries. Cox regression models adjusted for baseline comorbidities, age, sex, year of TAVI, social factors, and smoking were used to estimate mortality risk. Median follow-up was 1.9 years (interquartile range: 0.9–3.3). Overall, 5924 patients were included (47.3% women), with a mean age of 82.1 years (standard deviation: 6.1). Of the 1410 (23.8%) deaths during follow-up, 721 (51.2%) were related to cardiovascular causes. Patients with low education (12 years; adjusted hazard ratio (aHR): 1.20, 95% confidence interval (CI): 1.03–1.41]. Never being married/cohabiting was associated with an increased risk of mortality in comparison with being married/cohabiting (aHR: 1.32, 95% CI: 1.05–1.65). A separate analysis of men and women showed an increased risk among never-married men (aHR: 1.63, 95% CI: 1.23–2.14) but not among never-married women (aHR: 0.85, 95% CI: 0.56–1.30). Conclusion: Disadvantage in social factors was associated with an increased mortality risk after TAVI in older patients. These findings emphasize the importance of developing strategies to increase health literacy and social support after TAVI in older patients with unfavourable social factors.
- 31 August 2024
- Published by Oxford University Press (OUP) in European Heart Journal Open
- Vol. 4 (5) , oeae077
Open AccessMarital status, educational level, and mid-term mortality risk in 5924 patients after transcatheter aortic valve implantation
Aims: There is scarce knowledge about the association between social factors and mid-term outcome in older patients undergoing transaortic valve implantation (TAVI). Our aim in this study is to explore associations between marital status, educational level, and mortality risk in patients after TAVI. Methods and results: Patients aged ≥65 who underwent TAVI in Sweden during 2014–2020 were identified from the SWEDEHEART registry. Social factors and comorbidities were collected from mandatory national registries. Cox regression models adjusted for baseline comorbidities, age, sex, year of TAVI, social factors, and smoking were used to estimate mortality risk. Median follow-up was 1.9 years (interquartile range: 0.9–3.3). Overall, 5924 patients were included (47.3% women), with a mean age of 82.1 years (standard deviation: 6.1). Of the 1410 (23.8%) deaths during follow-up, 721 (51.2%) were related to cardiovascular causes. Patients with low education (12 years; adjusted hazard ratio (aHR): 1.20, 95% confidence interval (CI): 1.03–1.41]. Never being married/cohabiting was associated with an increased risk of mortality in comparison with being married/cohabiting (aHR: 1.32, 95% CI: 1.05–1.65). A separate analysis of men and women showed an increased risk among never-married men (aHR: 1.63, 95% CI: 1.23–2.14) but not among never-married women (aHR: 0.85, 95% CI: 0.56–1.30). Conclusion: Disadvantage in social factors was associated with an increased mortality risk after TAVI in older patients. These findings emphasize the importance of developing strategies to increase health literacy and social support after TAVI in older patients with unfavourable social factors.
- Open Access
- 16 January 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (2) , e031392
Impact of Down Syndrome on Survival Among Patients With Congenital Heart Disease
Background: Increasing survival among patients with congenital heart disease (CHD) has recently been reported. However, the impact of Down syndrome (DS) in patients with CHD is still debated. We aimed to estimate survival in patients with CHD with versus without DS compared with matched controls from the general population without CHD or DS. Methods and Results: We linked data from Swedish health registries to identify patients with CHD born between 1970 and 2017. Data from the Total Population Register were used to match each patient with CHD by sex and birth year with 8 controls without CHD or DS. A Cox proportional regression model was used to estimate mortality risk, and Kaplan–Meier curves were analyzed for the survival analysis. We identified 3285 patients with CHD‐DS, 64 529 patients with CHD without DS, and 26 128 matched controls. The mortality risk was 25.1 times higher (95% CI, 21.3–29.5) in patients with CHD‐DS versus controls. The mortality rate was 2 times higher (95% CI, 1.94–2.31) for patients with CHD with versus without DS. Lower mortality was found during the second versus first birth periods in patients with CHD‐DS compared with controls; hazard ratio: 46.8 (95% CI, 29.5–74.0) and 17.7 (95% CI, 12.8–24.42) in those born between 1970 and 1989 versus 1990 and 2017, respectively. Conclusions: In this retrospective cohort study, the mortality risk among patients with CHD‐DS was 25 times higher compared with matched controls and 2 times higher compared with patients with CHD without DS. Survival was higher in patients with CHD‐DS born after versus before 1990, coinciding with the modern era of congenital heart care.
- 16 January 2024
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 13 (2) , e031392
Open AccessImpact of Down Syndrome on Survival Among Patients With Congenital Heart Disease
Background: Increasing survival among patients with congenital heart disease (CHD) has recently been reported. However, the impact of Down syndrome (DS) in patients with CHD is still debated. We aimed to estimate survival in patients with CHD with versus without DS compared with matched controls from the general population without CHD or DS. Methods and Results: We linked data from Swedish health registries to identify patients with CHD born between 1970 and 2017. Data from the Total Population Register were used to match each patient with CHD by sex and birth year with 8 controls without CHD or DS. A Cox proportional regression model was used to estimate mortality risk, and Kaplan–Meier curves were analyzed for the survival analysis. We identified 3285 patients with CHD‐DS, 64 529 patients with CHD without DS, and 26 128 matched controls. The mortality risk was 25.1 times higher (95% CI, 21.3–29.5) in patients with CHD‐DS versus controls. The mortality rate was 2 times higher (95% CI, 1.94–2.31) for patients with CHD with versus without DS. Lower mortality was found during the second versus first birth periods in patients with CHD‐DS compared with controls; hazard ratio: 46.8 (95% CI, 29.5–74.0) and 17.7 (95% CI, 12.8–24.42) in those born between 1970 and 1989 versus 1990 and 2017, respectively. Conclusions: In this retrospective cohort study, the mortality risk among patients with CHD‐DS was 25 times higher compared with matched controls and 2 times higher compared with patients with CHD without DS. Survival was higher in patients with CHD‐DS born after versus before 1990, coinciding with the modern era of congenital heart care.
- Top Cited PapersOpen Access
- 21 March 2023
- Published by Wolters Kluwer Health in Circulation
- Vol. 147 (12) , 930-938
Adults With Congenital Heart Disease: Trends in Event-Free Survival Past Middle Age
Background: The survival of children with congenital heart disease has increased substantially over the past decades, with 97% currently reaching adulthood. The total effect of advanced treatment on future mortality and morbidity in adult survivors with congenital heart disease (CHD) is less well described. Methods: We used data from the Swedish National Inpatient, Outpatient, and Cause of Death Register to identify patients with CHD who were born between 1950 and 1999 and were alive at 18 years of age. Ten controls identified from the Total Population Register were matched for year of birth and sex and with each patient with CHD. Follow-up was from 1968 and 18 years of age until death or at the end of the study (2017). Survival percentage with 95% CI for all-cause mortality were performed with Kaplan-Meier survival function. Cox proportional hazard regression models with hazard ratios (HRs) and 95% CI were used to estimate the risk of all-cause mortality. Results: We included 37 278 patients with adult CHD (ACHD) and 412 799 controls. Mean follow-up was 19.2 years (±13.6). Altogether, 1937 patients with ACHD (5.2%) and 6690 controls (1.6%) died, a death rate of 2.73 per 1000 person-years and 0.84 per 1000 person years, respectively. Mortality was 3.2 times higher (95% CI, 3.0–3.4; P 75% of patients with ACHD were still alive. Mortality was highest among patients with conotruncal defects (HR, 10.13 [95% CI, 8.78–11.69]), but also significantly higher for the more benign lesions, with the lowest risk in patients with atrial septal defects (HR, 1.36 [95% CI, 1.19–1.55]). At least 75% of patients with ACHD alive at 18 years of age lived past middle age and became sexagenerians. Conclusions: In this large, nationwide, register-based cohort study of patients with ACHD surviving to 18 years of age, the risk of mortality up to 68 years of age was >3 times higher compared with matched controls without ACHD. Despite this, at least 75% of patients with CHD alive at 18 years of age lived past middle age and became sexagenerians. A notable risk decline in the mortality for patients with ACHD was seen for those born after 1975.
- 21 March 2023
- Published by Wolters Kluwer Health in Circulation
- Vol. 147 (12) , 930-938
Top Cited PapersOpen AccessAdults With Congenital Heart Disease: Trends in Event-Free Survival Past Middle Age
Background: The survival of children with congenital heart disease has increased substantially over the past decades, with 97% currently reaching adulthood. The total effect of advanced treatment on future mortality and morbidity in adult survivors with congenital heart disease (CHD) is less well described. Methods: We used data from the Swedish National Inpatient, Outpatient, and Cause of Death Register to identify patients with CHD who were born between 1950 and 1999 and were alive at 18 years of age. Ten controls identified from the Total Population Register were matched for year of birth and sex and with each patient with CHD. Follow-up was from 1968 and 18 years of age until death or at the end of the study (2017). Survival percentage with 95% CI for all-cause mortality were performed with Kaplan-Meier survival function. Cox proportional hazard regression models with hazard ratios (HRs) and 95% CI were used to estimate the risk of all-cause mortality. Results: We included 37 278 patients with adult CHD (ACHD) and 412 799 controls. Mean follow-up was 19.2 years (±13.6). Altogether, 1937 patients with ACHD (5.2%) and 6690 controls (1.6%) died, a death rate of 2.73 per 1000 person-years and 0.84 per 1000 person years, respectively. Mortality was 3.2 times higher (95% CI, 3.0–3.4; P 75% of patients with ACHD were still alive. Mortality was highest among patients with conotruncal defects (HR, 10.13 [95% CI, 8.78–11.69]), but also significantly higher for the more benign lesions, with the lowest risk in patients with atrial septal defects (HR, 1.36 [95% CI, 1.19–1.55]). At least 75% of patients with ACHD alive at 18 years of age lived past middle age and became sexagenerians. Conclusions: In this large, nationwide, register-based cohort study of patients with ACHD surviving to 18 years of age, the risk of mortality up to 68 years of age was >3 times higher compared with matched controls without ACHD. Despite this, at least 75% of patients with CHD alive at 18 years of age lived past middle age and became sexagenerians. A notable risk decline in the mortality for patients with ACHD was seen for those born after 1975.
- 21 March 2023
- Published by Wolters Kluwer Health in Circulation
- Vol. 147 (12) , 982-984
Risk of Heart Failure in Congenital Heart Disease: A Nationwide Register-Based Cohort Study
- 21 March 2023
- Published by Wolters Kluwer Health in Circulation
- Vol. 147 (12) , 982-984
Risk of Heart Failure in Congenital Heart Disease: A Nationwide Register-Based Cohort Study